Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9OH
|
|||
| Former ID |
DNCL002207
|
|||
| Drug Name |
L-MDAM
|
|||
| Synonyms |
L-MDAM; 176857-41-3; UNII-W9CXL7O6LL; W9CXL7O6LL; GAMMA-METHYLENE-10-DEAZAAMINOPTERIN; MDAM; SCHEMBL1065136; ZINC1542008; KB-78169; Z-3290; L-Glutamic acid, N-(4-(2-(2,4-diamino-6-pteridinyl)ethyl)benzoyl)-4-methylene-; (2S)-2-[4-[2-(2,4-Diamino-6-pteridinyl)ethyl]benzoylamino]-4-methyleneglutaric acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
BioNumerik Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21N7O5
|
|||
| Canonical SMILES |
C=C(CC(C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)O
|
|||
| InChI |
1S/C21H21N7O5/c1-10(19(30)31)8-14(20(32)33)26-18(29)12-5-2-11(3-6-12)4-7-13-9-24-17-15(25-13)16(22)27-21(23)28-17/h2-3,5-6,9,14H,1,4,7-8H2,(H,26,29)(H,30,31)(H,32,33)(H4,22,23,24,27,28)/t14-/m0/s1
|
|||
| InChIKey |
QCLDSHDOWCMFBV-AWEZNQCLSA-N
|
|||
| CAS Number |
CAS 176857-41-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dihydrofolate reductase (DHFR) | Target Info | Inhibitor | [2] |
| KEGG Pathway | One carbon pool by folate | |||
| Folate biosynthesis | ||||
| Metabolic pathways | ||||
| Panther Pathway | Tetrahydrofolate biosynthesis | |||
| Formyltetrahydroformate biosynthesis | ||||
| Pathwhiz Pathway | Folate Metabolism | |||
| Pterine Biosynthesis | ||||
| Pathway Interaction Database | E2F transcription factor network | |||
| Reactome | E2F mediated regulation of DNA replication | |||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | ||||
| Metabolism of folate and pterines | ||||
| G1/S-Specific Transcription | ||||
| WikiPathways | Nucleotide Metabolism | |||
| Trans-sulfuration and one carbon metabolism | ||||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Metabolism of nitric oxide | ||||
| Folate Metabolism | ||||
| Fluoropyrimidine Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006614) | |||
| REF 2 | Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.